Transform the Way You Manage Early-Stage Melanomas

Every melanoma is unique. Patients with the same clinical stage may still have very different tumor biology, resulting in wide variation in their risk of metastasis and recurrence. Traditional staging alone may fail to capture these biological differences, leading to misclassification of metastatic risk at diagnosis and, consequently, to potential overtreatment or undertreatment.

The Merlin Test delivers personalized, molecular-based predictive and prognostic insights that complement traditional staging and improve the accuracy of melanoma risk assessment -helping guide more precise care for each patient.

Current treatment decisions often rely on clinicopathologic factors such as patient age, Breslow thickness, and ulceration. While important, these variables alone do not always capture the full picture of a patient’s melanoma or their individual risk. The Merlin Test offers a more comprehensive understanding of your patient’s cancer – without requiring any additional procedures.

Using the CP-GEP model, an algorithm developed through logistic regression, the Merlin Test integrates clinicopathologic features (age and Breslow thickness) with gene expression data from 8 key genes associated with melanoma metastasis. This combined approach provides personalized predictive insights, helping you better assess risk and optimize treatment planning.

The Merlin Test enhances clinical management by providing reliable risk stratification for each patient. Validated in multiple multicenter studies across the United States and Europe, the test consistently distinguishes two clinically meaningful patient groups, delivering a straightforward binary result that informs treatment decisions.